Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2681-2700 of 3,900 trials

Sepsis-Induced Hypotension: REGN7544 Treatment Study

We are studying REGN7544 to see if it can help adults with sepsis-induced hypotension manage their blood pressure and reduce the need for other medications. The trial will also assess the safety and effects of this treatment.

Sepsis-Induced Hypotension3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInfectious Diseases

Lung Cancer: BMS-986507 Treatment Study

We are testing a new treatment called BMS-986507 for adults with advanced lung cancer to see if it is safe and to find the best dose when used with other therapies.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Staphylococcus Aureus Bloodstream Infections: Dalbavancin Study

We are testing a single dose of intravenous Dalbavancin against standard antibiotics for patients with bloodstream infections. The goal is to see if Dalbavancin is as effective and to evaluate its impact on recovery and quality of life.

Catheter-Related Bloodstream Infections3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Squamous Cell Carcinoma: Cetuximab with or without Paclitaxel

We are studying the effectiveness of cetuximab alone or with paclitaxel for patients with recurrent head and neck cancer after previous treatment. The goal is to see how these options affect survival and quality of life.

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Peripheral T-Cell Lymphoma: New Drug Evaluation

We are testing new drugs for patients with relapsed or refractory peripheral T-cell lymphomas to see if they are safe and improve treatment outcomes. This trial aims to find better options for those who have not responded to existing therapies.

Relapsed or Refractory Peripheral T-Cell Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: CAR-T Therapy vs. Rituximab

We are comparing a new CAR-T cell therapy with rituximab for patients with active rheumatoid arthritis that hasn't responded to other treatments. The goal is to see which therapy is safer and more effective.

Rheumatoid Arthritis1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesRheumatology

Avapritinib: Continued Access for Previous Study Participants

We are offering ongoing access to avapritinib for adults who benefited from it in a prior study. This trial also aims to evaluate the long-term safety of the treatment.

Systemic Mastocytosis6-12 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Myotonia Treatment: Mexiletine PR vs. Mexiletine IR

We are comparing two forms of mexiletine to see which one is safer and more effective for adults with non-dystrophic myotonias. This study aims to improve treatment options for conditions like myotonia congenita and paramyotonia congenita.

Myotonic DystrophyNon-Dystrophic Myotonias6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Thyroid Eye Disease: VRDN-003 Treatment Study

We are investigating whether VRDN-003 can improve symptoms in individuals with active thyroid eye disease. The study will also check if the treatment is safe and well-tolerated compared to a placebo.

Thyroid Eye Disease1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology

Seizures in Developmental and Epileptic Encephalopathy: Bexicaserin (LP352)

We are studying the safety and effectiveness of a new medication, bexicaserin, for treating seizures in children and adults with developmental and epileptic encephalopathy. This research aims to understand how well it works for managing their condition.

Developmental and Epileptic Encephalopathies1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Rheumatoid Arthritis: AP1189 with Methotrexate

We are studying a new oral medication, AP1189, for people with early rheumatoid arthritis who haven't received other treatments. The goal is to see if it works better with methotrexate than methotrexate alone.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementRheumatology

Bladder Cancer: Sacituzumab Tirumotecan Study

We are investigating the effects of sacituzumab tirumotecan in individuals with bladder cancer. This study aims to see how well this treatment works compared to standard options.

Intermediate-risk Non-muscle Invasive Bladder Cancer>2 yearsSafety phase (I)Efficacy phase (II)OncologyUrology

Multiple Myeloma: Isatuximab with Novel Agents

We are studying a new combination treatment for people with relapsed or refractory multiple myeloma. This trial aims to find effective doses and evaluate how well these combinations work compared to standard treatments.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Belumosudil and Dexamethasone

We are studying a new combination of treatments for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if this combination improves treatment outcomes.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Evorpacept and Dexamethasone

We are studying a new treatment combination for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if it improves treatment responses compared to existing options.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Hemoptysis Treatment: TXA vs. Terlipressin

We are studying whether inhaled tranexamic acid or terlipressin can help control coughing up blood in hospitalized patients. The goal is to see if these treatments work better than a placebo in managing this serious condition.

Coughing Up Blood (Hemoptysis)Confirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInternal MedicinePulmonology

Cancer Pain Management: Paracetamol with Opioids

We are studying whether stopping paracetamol affects pain control in patients using strong opioids for cancer-related pain. We also want to see if this change impacts side effects and overall patient satisfaction.

Metastatic Cancer≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicineOncology

Nephrogenic Diabetes Insipidus: Amiloride Treatment Study

We are investigating whether amiloride can help patients with nephrogenic diabetes insipidus caused by lithium treatment for bipolar disorder. The study looks at its effects on urine concentration, thirst, and quality of life.

Bipolar Disorder with Lithium Treatment>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNephrologyPsychiatry

Septic Shock: Ivabradine for Heart Rate Control

We are studying whether Ivabradine can help control heart rate and improve survival in patients with septic shock. This trial compares the medication to a placebo to assess its effectiveness.

Septic Shock>2 yearsConfirmation phase (III)Standard MedicinesCardiologyInfectious DiseasesInternal Medicine

Advanced Cancers: New Treatment Study

We are exploring a new treatment option for patients with advanced cancers. This study aims to see if it can improve outcomes compared to standard care.

Advanced Solid TumourSafety phase (I)Efficacy phase (II)Oncology